Financetoday
financialTelegram

Lilly Raises Outlook Again as Zepbound Sales Keep Climbing

Pharma·October 29, 2026

Lilly Raises Outlook Again as Zepbound Sales Keep Climbing

Eli Lilly has raised its financial outlook for the third time this year, a sign that demand for Zepbound is running ahead of the drugmaker's own expectations. The upgrade points to a product that has moved from a promising launch to a central driver of the company's growth.

Zepbound, which contains the active ingredient tirzepatide, belongs to the GLP-1 class of drugs that mimic gut hormones involved in appetite and blood sugar control. It remains the dominant prescription option for weight loss in the United States, and its steady uptake has been the main reason Lilly keeps revising its numbers upward.

Repeated guidance increases within one year are unusual for a company of Lilly's size. They suggest prescriptions are climbing faster than analysts had modeled, not that the company is benefiting from a single one-time boost. That makes the next stretch a test of whether the momentum holds.

Investors will be watching competition closely. Novo Nordisk, which sells the rival obesity drug Wegovy, is also pushing for share of the same patients, and insurers and employers continue to debate how broadly to cover obesity treatments. Lilly's diabetes product Mounjaro uses the same molecule as Zepbound, so the company's gains in this drug class reach beyond weight loss alone.

For now, the revised outlook gives Lilly room to argue that its position is strengthening rather than peaking.

Reporting based on an external source.